We are live on
!
Find out more
FP
Foundry Partners Portfolio holdings
AUM
$1.89B
1-Year Est. Return
9.84%
This Fund
S&P 500
This Quarter
Est. Return
+1.27%
1 Year Est. Return
+9.84%
3 Year Est. Return
+44.42%
5 Year Est. Return
+233.04%
10 Year Est. Return
+297.72%
AUM
$2.42B
AUM Growth
-$119M
(-4.7%)
Cap. Flow
-$116M
Cap. Flow
% of AUM
-4.8%
Top 10 Holdings %
Top 10 Hldgs %
11.89%
Holding
424
New
35
Increased
125
Reduced
216
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Altria Group
MO
|
+$22.3M |
| 2 |
AES
AES
|
+$14M |
| 3 |
SNV
Synovus
SNV
|
+$13.3M |
| 4 |
Delta Air Lines
DAL
|
+$12.8M |
| 5 |
Albemarle
ALB
|
+$11.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$21.4M |
| 2 |
Cisco
CSCO
|
+$18.9M |
| 3 |
Johnson & Johnson
JNJ
|
+$16.4M |
| 4 |
HP
HPQ
|
+$13.9M |
| 5 |
GSK
GSK
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.35% |
| 2 | Industrials | 15.2% |
| 3 | Technology | 9.4% |
| 4 | Healthcare | 8.25% |
| 5 | Consumer Discretionary | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PFIE
301
DELISTED
Profire Energy, Inc
PFIE
| $1.26M | 0.05% |
666,750
-39,475
| -6% | -$60.2K |
|
|
BPMC
302
DELISTED
Blueprint Medicines
BPMC
| $1.25M | 0.05% |
16,992
+812
| +5% | +$70.2K |
|
|
SRGA
303
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $1.24M | 0.05% |
14,555
-816
| -5% | -$87.1K |
|
304
Central Garden & Pet Co
CENT
$2.69B
| $1.22M | 0.05% |
52,146
-123
| -0.2% | -$2.66K |
|
305
AMC Global Media
AMCX
$430M
| $1.18M | 0.05% |
23,930
-56
| -0.2% | -$2.89K |
|
|
HBMD
306
DELISTED
Howard Bancorp, Inc. Common Stock
HBMD
| $1.15M | 0.05% |
68,840
-4,150
| -6% | -$62.6K |
|
307
Zoetis
ZTS
$31.3B
| $1.09M | 0.04% |
8,736
-1,003
| -10% | -$121K |
|
308
Armstrong World Industries
AWI
$6.75B
| $1.04M | 0.04% |
10,804
-13,729
| -56% | -$1.32M |
|
|
FISV
309
Fiserv Inc
FISV
$26.6B
| $1.04M | 0.04% |
10,022
-1,325
| -12% | -$135K |
|
310
Ooma
OOMA
$532M
| $1.03M | 0.04% |
98,929
-232
| -0.2% | -$2.72K |
|
311
Cal-Maine
CALM
$4.18B
| $1.03M | 0.04% |
25,707
-56
| -0.2% | -$2.33K |
|
312
Yelp
YELP
$1.35B
| $1.01M | 0.04% |
29,037
-9,633
| -25% | -$333K |
|
313
Apple
AAPL
$4.72T
| $1M | 0.04% |
17,908
-1,480
| -8% | -$77.4K |
|
314
Visa
V
$669B
| $993K | 0.04% |
5,772
-375
| -6% | -$66.8K |
|
315
Intercontinental Exchange
ICE
$81B
| $990K | 0.04% |
10,728
-600
| -5% | -$54.8K |
|
|
WBT
316
DELISTED
Welbilt, Inc.
WBT
| $984K | 0.04% |
58,368
-136
| -0.2% | -$2.21K |
|
317
InterDigital
IDCC
$6.62B
| $977K | 0.04% |
18,618
-44
| -0.2% | -$2.49K |
|
318
Microsoft
MSFT
$2.83T
| $967K | 0.04% |
6,955
-425
| -6% | -$58.4K |
|
319
Edwards Lifesciences
EW
$48.3B
| $966K | 0.04% |
13,182
-1,911
| -13% | -$134K |
|
320
Amphenol
APH
$194B
| $962K | 0.04% |
39,864
-2,200
| -5% | -$50.7K |
|
|
GWB
321
DELISTED
Great Western Bancorp, Inc.
GWB
| $945K | 0.04% |
28,643
-67
| -0.2% | -$2.16K |
|
322
Ligand Pharmaceuticals
LGND
$6.06B
| $916K | 0.04% |
14,752
-34
| -0.2% | -$2.13K |
|
|
RDUS
323
DELISTED
Radius Health, Inc.
RDUS
| $832K | 0.03% |
+32,322
| New | +$792K |
|
324
Home Depot
HD
$324B
| $771K | 0.03% |
3,325
-225
| -6% | -$49.2K |
|
325
Alphabet (Google) Class A
GOOGL
$3.88T
| $751K | 0.03% |
12,300
-500
| -4% | -$29.6K |
|
Similar funds
ST
UH
PAME
TW
AP
MBA
SSB
CC
Foundry Partners's Q3 2019 Portfolio in Review
As of Q3 2019, Foundry Partners held 424 positions worth $2.42B, down 4.7% from $2.54B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Foundry Partners withdrew a net $116M in Q3 2019, closing 37 positions and reducing 216 holdings. Its most notable exit was Allergan plc, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Financials at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Technology.
Against the trend, Foundry Partners opened a new position in Altria Group worth $19.8M.
- Foundry Partners's largest Q3 2019 buy was Altria Group: 484,800 shares worth $19.8M.
- Foundry Partners added most to Gilead Sciences in Q3 2019, an estimated $11.6M increase.
- Foundry Partners's biggest Q3 2019 reduction was Cisco, cutting an estimated $18.9M.
- Foundry Partners fully exited Allergan plc in Q3 2019, selling an estimated $21.4M.
- Foundry Partners's ten largest holdings make up 12% of its $2.42B portfolio in Q3 2019.
- Foundry Partners opened 35 new positions and closed 37 in Q3 2019.
- Foundry Partners's portfolio value fell 4.7% quarter-over-quarter to $2.42B.
Based on Foundry Partners's 13F filing for Q3 2019, filed 23 Oct 2019.